{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T21:06:21Z","timestamp":1779483981541,"version":"3.53.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fondazione Policlinico Universitario A. Gemelli IRCCS"},{"DOI":"10.13039\/501100014091","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014091","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovation Sprint"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The \u2018FondAZione A. Gemelli IRCCS Artificial Intelligence Empowered Digital PlatforM to sUpport paTients with Heart Failure\u2019 (AZIMUTH) study is a multicentre prospective outpatient trial assessing an app-based, e-health-integrated model of care for heart failure (HF) patients. Its primary aim is to evaluate the feasibility and patient\/provider acceptance of the app-based intervention, while key secondary aims include assessing its clinical impact through changes in guideline-directed medical therapy (GDMT) prescription\/adherence and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Feasibility is defined as \u226570% of participants maintaining active engagement with the app during follow-up. The platform integrates patient-reported symptoms, connected measurements, medication reminders, and two-way messaging, with clinician review of alerts and trends. Between December 2021 and January 2024, 300 adults with chronic HF, irrespective of left ventricular ejection fraction (LVEF), were enrolled across four Italian centres. Median age was 66 years (IQR 59\u201373), 78.3% were male, and 82.3% were NYHA Class I\u2013II. LVEF distribution was balanced (HFrEF 35.3%, HFmrEF 25.7%, HFpEF 38.7%). Comorbidities were frequent: hypertension 81.3%, dyslipidaemia 75.7%, ischaemic heart disease 41.0%, diabetes 29.7%, atrial fibrillation 29.7%, and chronic kidney disease 21.7%. At enrolment, RASi\/ARNI were prescribed in 69.6%, beta-blockers in 76.9%, MRAs in 16.1%, and SGLT2i in 23.7%. Compared with HFrEF-focused trials, uptake of foundational classes was lower, consistent with the broader LVEF spectrum and real-world constraints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The AZIMUTH cohort represents a contemporary, heterogeneous HF population with variable and suboptimal GDMT uptake. Digital health interventions have the potential to optimize care delivery and increase adherence in real-world settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjopen\/oeag072","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:25:41Z","timestamp":1777577141000},"source":"Crossref","is-referenced-by-count":0,"title":["Baseline characteristics of patients enrolled in the AZIMUTH trial: an e-health-integrated, smartphone app-based model of care for heart failure patients"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3774-8330","authenticated-orcid":false,"given":"Domenico","family":"D\u2019Amario","sequence":"first","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, Novara 28100 ,","place":["Italy"]},{"name":"Thoraco-Cardio-Vascular Department, Azienda Ospedaliero-Universitaria Maggiore Della Carit\u00e0 , Viale Mazzini 18, Novara 28100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-4809","authenticated-orcid":false,"given":"Donato Antonio","family":"Paglianiti","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, Novara 28100 ,","place":["Italy"]},{"name":"Thoraco-Cardio-Vascular Department, Azienda Ospedaliero-Universitaria Maggiore Della Carit\u00e0 , Viale Mazzini 18, Novara 28100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Laborante","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, Karolinska Institutet , Sjukhusbacken 10, Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Elia","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, Novara 28100 ,","place":["Italy"]},{"name":"Thoraco-Cardio-Vascular Department, Azienda Ospedaliero-Universitaria Maggiore Della Carit\u00e0 , Viale Mazzini 18, Novara 28100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, Novara 28100 ,","place":["Italy"]},{"name":"Thoraco-Cardio-Vascular Department, Azienda Ospedaliero-Universitaria Maggiore Della Carit\u00e0 , Viale Mazzini 18, Novara 28100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Giubilato","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cannizzaro Hospital , Via Messina 829, Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Catalano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cannizzaro Hospital , Via Messina 829, Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Amico","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cannizzaro Hospital , Via Messina 829, Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-9213","authenticated-orcid":false,"given":"Maurizio","family":"Volterrani","sequence":"additional","affiliation":[{"name":"Department of Cardiopulmonary, IRCCS San Raffaele Roma , Via della Pisana 235, Rome 00166 ,","place":["Italy"]},{"name":"Universit\u00e1 San Raffaele , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9097-5287","authenticated-orcid":false,"given":"Attilio","family":"Restivo","sequence":"additional","affiliation":[{"name":"Catholic University of the Sacred Heart , Largo F. Vito 1, 00168, Rome ,","place":["Italy"]},{"name":"Cardio-Neuro-Vascular Department, Cardiology Unit, Ca\u2019 Foncello Hospital and San Giacomo Hospital , Treviso and Castelfranco Veneto, Piazzale Ospedale 1, 31100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Patarnello","sequence":"additional","affiliation":[{"name":"Fondazione Universitaria Policlinico A. Gemelli IRCCS , Largo. A. Gemelli 8, 00168, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofoklis","family":"Kyriazakos","sequence":"additional","affiliation":[{"name":"Innovation Sprint Srl , Brussels, Clos Chapelle-aux-Champs 30, Bruxelles ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Luraschi","sequence":"additional","affiliation":[{"name":"Fondazione Universitaria Policlinico A. Gemelli IRCCS , Largo. A. Gemelli 8, 00168, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agni","family":"Delvinioti","sequence":"additional","affiliation":[{"name":"Fondazione Universitaria Policlinico A. Gemelli IRCCS , Largo. A. Gemelli 8, 00168, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Tomassini","sequence":"additional","affiliation":[{"name":"Fondazione Universitaria Policlinico A. Gemelli IRCCS , Largo. A. Gemelli 8, 00168, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Kostopoulou","sequence":"additional","affiliation":[{"name":"Innovation Sprint Srl , Brussels, Clos Chapelle-aux-Champs 30, Bruxelles ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7413-8449","authenticated-orcid":false,"given":"Antonio","family":"Iaconelli","sequence":"additional","affiliation":[{"name":"Catholic University of the Sacred Heart , Largo F. Vito 1, 00168, Rome ,","place":["Italy"]},{"name":"Fondazione Universitaria Policlinico A. Gemelli IRCCS , Largo. A. Gemelli 8, 00168, Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Incaminato","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, Novara 28100 ,","place":["Italy"]},{"name":"Thoraco-Cardio-Vascular Department, Azienda Ospedaliero-Universitaria Maggiore Della Carit\u00e0 , Viale Mazzini 18, Novara 28100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Canonico","sequence":"additional","affiliation":[{"name":"Thoraco-Cardio-Vascular Department, Azienda Ospedaliero-Universitaria Maggiore Della Carit\u00e0 , Viale Mazzini 18, Novara 28100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gorini","sequence":"additional","affiliation":[{"name":"Healthcare Innovation, AstraZeneca , V.le Decumano 39, 20157, Rho ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Marcoli","sequence":"additional","affiliation":[{"name":"Healthcare Innovation, AstraZeneca , V.le Decumano 39, 20157, Rho ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bartoli","sequence":"additional","affiliation":[{"name":"Healthcare Innovation, AstraZeneca , V.le Decumano 39, 20157, Rho ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Healthcare Service Design, AstraZeneca , Pancras Sq, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fenici","sequence":"additional","affiliation":[{"name":"Catholic University of the Sacred Heart , Largo F. Vito 1, 00168, Rome ,","place":["Italy"]},{"name":"Healthcare Innovation, AstraZeneca , V.le Decumano 39, 20157, Rho ,","place":["Italy"]},{"name":"Biomagnetism and Clinical Physiology International Center (BACPIC) , Largo A. Gemelli 1, 00168 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Cesario","sequence":"additional","affiliation":[{"name":"Catholic University of the Sacred Heart , Largo F. Vito 1, 00168, Rome ,","place":["Italy"]},{"name":"Fondazione Universitaria Policlinico A. Gemelli IRCCS , Largo. A. Gemelli 8, 00168, Rome ,","place":["Italy"]},{"name":"Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli IRCCS , Largo A. Gemelli 1, 00168, Rome ,","place":["Italy"]},{"name":"Gemelli Digital Medicine and Health , Largo A. Gemelli 8, 00168 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-3968","authenticated-orcid":false,"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont , Via Solaroli 17, Novara 28100 ,","place":["Italy"]},{"name":"Thoraco-Cardio-Vascular Department, Azienda Ospedaliero-Universitaria Maggiore Della Carit\u00e0 , Viale Mazzini 18, Novara 28100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[{"name":"Catholic University of the Sacred Heart , Largo F. Vito 1, 00168, Rome ,","place":["Italy"]},{"name":"Center of Excellence of Cardiovascular Sciences, Ospedale Isola Tiberina\u2013Gemelli Isola , Via Ponte Quattro Capi 39, 00186 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2026052216292030800_oeag072-B1","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026052216292030800_oeag072-B2","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/ejhf.3295","article-title":"How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026052216292030800_oeag072-B3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ejhf.2477","article-title":"Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry","volume":"24","author":"D\u2019Amario","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026052216292030800_oeag072-B4","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/ejhf.2655","article-title":"Device-based remote monitoring strategies for congestion-guided management of patients with heart failure: a systematic review and meta-analysis","volume":"24","author":"Zito","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026052216292030800_oeag072-B5","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.899656","article-title":"A 3-year single center experience with left atrial pressure remote monitoring: the long and winding road","volume":"9","author":"Restivo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026052216292030800_oeag072-B6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ehjdh\/ztaf040","article-title":"Study design and rationale of the AZIMUTH trial: a smartphone, app-based, E-health-integrated model of care for heart failure patients","volume":"6","author":"D\u2019Amario","year":"2025","journal-title":"Eur Heart J Digit Health"},{"key":"2026052216292030800_oeag072-B7","author":"Versions History [Internet]"},{"key":"2026052216292030800_oeag072-B8","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"2026052216292030800_oeag072-B9"},{"key":"2026052216292030800_oeag072-B10","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026052216292030800_oeag072-B11","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026052216292030800_oeag072-B12","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026052216292030800_oeag072-B13","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026052216292030800_oeag072-B14","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026052216292030800_oeag072-B15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2026052216292030800_oeag072-B16","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026052216292030800_oeag072-B17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1164\/rccm.202301-0106PP","article-title":"Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary","volume":"207","author":"Agust\u00ed","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026052216292030800_oeag072-B18","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1104699","article-title":"GENERATOR HEART FAILURE DataMart: an integrated framework for heart failure research","volume":"10","author":"D\u2019Amario","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026052216292030800_oeag072-B19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026052216292030800_oeag072-B20","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026052216292030800_oeag072-B21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026052216292030800_oeag072-B22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026052216292030800_oeag072-B23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"2026052216292030800_oeag072-B24","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","article-title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"406","author":"Butler","year":"2025","journal-title":"Lancet"},{"key":"2026052216292030800_oeag072-B25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026052216292030800_oeag072-B26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF registry","volume":"7","author":"Brunner-La Rocca","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026052216292030800_oeag072-B27","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/ejhf.3260","article-title":"OPTImal PHARMacological therapy for patients with heart failure: rationale and design of the OPTIPHARM-HF registry","volume":"26","author":"Inciardi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026052216292030800_oeag072-B28","article-title":"Eligibility for the 4 pharmacological pillars in heart failure with reduced ejection fraction at discharge","volume":"12","author":"D\u2019Amario","year":"2023","journal-title":"JAHA"},{"key":"2026052216292030800_oeag072-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026052216292030800_oeag072-B30","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1056\/NEJMoa1010029","article-title":"Telemonitoring in patients with heart failure","volume":"363","author":"Chaudhry","year":"2010","journal-title":"N Engl J Med"},{"key":"2026052216292030800_oeag072-B31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2020.05.015","article-title":"Baroreflex activation therapy in patients with heart failure with reduced ejection fraction","volume":"76","author":"Zile","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026052216292030800_oeag072-B32","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ejhf.1300","article-title":"Telemedical interventional management in heart failure II (TIM-HF2), a randomised, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalisations and mortality in heart failure patients: study design and description of the intervention","volume":"20","author":"Koehler","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026052216292030800_oeag072-B33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/17434440.2023.2196400","article-title":"The CardioMEMS heart failure system for chronic heart failure\u2014a European perspective","volume":"20","author":"Radhoe","year":"2023","journal-title":"Expert Rev Med Devices"},{"key":"2026052216292030800_oeag072-B34","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","article-title":"Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial","volume":"398","author":"Lindenfeld","year":"2021","journal-title":"Lancet"},{"key":"2026052216292030800_oeag072-B35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.1900","article-title":"Experience of remote cardiac care during the COVID-19 pandemic: the V-LAPTM device in advanced heart failure","volume":"22","author":"D\u2019Amario","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026052216292030800_oeag072-B36","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009462","article-title":"Temporal trends of heart failure hospitalizations in cardiology versus noncardiology wards according to ejection fraction: 16-year data from the SwedeHF registry","volume":"15","author":"Canepa","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026052216292030800_oeag072-B37","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjopen\/advance-article-pdf\/doi\/10.1093\/ehjopen\/oeag072\/68197527\/oeag072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/6\/3\/oeag072\/68197527\/oeag072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/6\/3\/oeag072\/68197527\/oeag072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T20:29:30Z","timestamp":1779481770000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjopen\/article\/doi\/10.1093\/ehjopen\/oeag072\/8665975"}},"subtitle":[],"editor":[{"given":"Linda","family":"Mellbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjopen\/oeag072","relation":{},"ISSN":["2752-4191"],"issn-type":[{"value":"2752-4191","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,30]]},"article-number":"oeag072"}}